Home › Merck Announces Samsung Bioepis Will Present New Biosimilars Data at the 2015 ACR/ARHP Annual Meeting
 

Keywords :   


Merck Announces Samsung Bioepis Will Present New Biosimilars Data at the 2015 ACR/ARHP Annual Meeting

2015-11-05 14:43:00| Merck.com - Research & Development News

Dateline City: KENILWORTH, N.J. One-Year Phase 3 Data for Investigational Biosimilar Candidates SB4, Enbrel (Etanercept) and SB2, Remicade (Infliximab) to be Presented for the First Time New Pivotal 24-Week Phase 3 Data for SB5, an Investigational Biosimilar of Humira (Adalimumab), to be Reported in Late-Breaking Presentation KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that Samsung Bioepis will present new Phase 3 clinical data for three investigational immunology biosimilar candidates at the American College of Rheumatology (ACR) and the Association for Rheumatology Health Professionals (ARHP) 2015 Annual Meeting in San Francisco, Nov. 7-11. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Robert Consalvo, 908-236-1127orInvestors:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: data present meeting annual

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
10.10Starbucks, Tetley, Jaguar Land Rover: Remembering Ratan Tata's global ambitions
10.10Hurricane Leslie Graphics
10.10Hurricane Milton Forecast Discussion Number 21
10.10Hurricane Leslie Wind Speed Probabilities Number 32
10.10Hurricane Milton Wind Speed Probabilities Number 21
10.10Hurricane Milton Public Advisory Number 21
10.10Hurricane Leslie Forecast Advisory Number 32
10.10Hurricane Leslie Public Advisory Number 32
More »